Marker Therapeutics (MRKR) Receivables - Other (2013 - 2026)

Marker Therapeutics (MRKR) has 10 years of Receivables - Other data on file, last reported at $1.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.3 million, down 42.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 42.57% YoY), and the FY2025 annual result was $50419.0, down 97.82% from the prior year.
• Receivables - Other advanced to $1.3 million in Q1 2026 per MRKR's latest filing, from $50419.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $2.4 million in Q4 2022 and troughed at $2185.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.0 million in 2023 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 1013403.8% in 2022 and fell as far as 99.78% in 2022.
• A 5-year view of Receivables - Other shows it stood at $2.4 million in 2022, then tumbled by 57.21% to $1.0 million in 2023, then soared by 125.39% to $2.3 million in 2024, then tumbled by 97.82% to $50419.0 in 2025, then surged by 2519.8% to $1.3 million in 2026.
• Business Quant data shows MRKR's Receivables - Other at $1.3 million in Q1 2026, $50419.0 in Q4 2025, and $600000.0 in Q3 2025.